Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Psychopharmacology Algorithms (April) | 2020

View Archived Issues

CME Post-Test - Psychopharmacology Algorithms, TCPR, April 2020

March 30, 2020

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit. Read More

How to Choose an Antipsychotic in Schizophrenia

March 30, 2020

Rehan Aziz, MD.

Atypical antipsychotics are more alike than different, but a few stand out for tolerability, while others may have an edge for negative symptoms or for overall efficacy. Read More

The Psychopharmacology Algorithm Project

March 30, 2020

David Osser, MD

Dr. Osser set out to develop a psychopharmacology algorithm that actually changes practice. He speaks to us on antidepressants in bipolar, psychoses that don’t need antipsychotics, and his top picks for bipolar mania, bipolar depression, and unipolar depression. Read More

Nuplazid: Novel Mechanism, Modest Benefits

March 30, 2020

Randall Moore, MD, JD. and Chris Aiken, MD.

Pimavanserin (Nuplazid) aims to treat psychosis without blocking dopamine. Though FDA-approved for psychosis associated with Parkinson’s disease, the drug is being tested in a host of other disorders: Depression, dementia, and sexual dysfunction. Read More

Antipsychotics Fall Short in Delirium

March 30, 2020

Adrienne Grzenda, MD.

Antipsychotics remain a mainstay of delirium treatment despite significant concerns about their safety and efficacy. A pair of reports recently evaluated the evidence on their use in delirium. Read More

Singulair and Suicide: FDA Strengthens Warning

March 30, 2020

After a rise of adverse psychiatric reports on montelukast (Singulair), an oral leukotriene inhibitor used for asthma and allergies, the FDA added a black box warning in March 2020 about mood and behavior changes including suicide. Read More